Prevalence of transfusion-transmitted infections in hospitalized patients before transfusion from volunteer donors in the Chinese province of Zhejiang

by | Feb 6, 2024 | Publications

Infect Dis Now. 2024 Feb 3:104861. doi: 10.1016/j.idnow.2024.104861. Online ahead of print.

ABSTRACT

OBJECTIVES: To assess the need for screening of transfusion-transmitted infections (TTIs) in blood products, we assessed TTI seroprevalence in blood donors and hospitalized patients.

METHODS: We collected 2760 serum samples from three regions of Hangzhou, Ningbo and Huzhou from April 2021 to March 2022, and they tested by enzyme-linked immunosorbent assay (ELISA) for Hepatitis B surface antigen (HBsAg), Hepatitis C (HCV), Treponema pallidum (TP), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Hepatitis E virus (HEV) and Human T-cell lymphotropic virus type 1/2 (HTLV-1/2) antibody levels.

RESULTS: Screening test results showed that the positive rates for HBsAg, anti-HCV and anti-TP were 3.01%, 0.39% and 0.18%, respectively. The positive rates for CMV IgM and CMV IgG were 0.76% and 96.96%, while the positive rates for EB VCA-IgM and EB EA-IgG were 1.88% and 10.47%; those for HEV IgM and HEV IgG were 1.16% and 26.05%, while the HTLV 1/2 antibody positive rate was 0.04%. The positive rates for CMV IgG, EB EA-IgG and HEV IgG in hospitalized patients before transfusion were higher than in volunteer blood donors, and the difference was statistically significant (P<0.05). The overall co-infection rate was 0.29%. The positive rates for EB VCA-IgM in the males were significantly higher than in females, and EB VCA-IgM and HEV IgG prevalence varied significantly by age.

CONCLUSION: Our data demonstrate the risk of TTI exposure and TTI transmission in the Zhejiang population, which poses a threat to blood safety. It is hoped that expansion of pathogen categories (CMV, EBV, HEV and HTLV-1/2) and blood screening programs will contribute to the future adoption of scientific blood transfusion methods.

PMID:38316362 | DOI:10.1016/j.idnow.2024.104861

Other publications you may be interested in…

HTLV-1 Disease

HTLV-1 Disease

HTLV-1 Disease Abstract The years 2020 and 2021 will remain memorable years for many reasons [...]. Click here to...

read more